BTG's (BTG) blood clot busting catheter Ekos, has proved effective in the treatment of patients with post-thrombotic syndrome (PTS) caused by chronic deep vein thrombosis. In a final phase clinical trial, patients treated using Ekos saw their symptoms improve by 34 per cent and their quality of life increase significantly.
IC TIP:
Buy
at
693p
This is the first PTS treatment to achieve such positive results in a final-stage clinical trial, which puts it in a strong position against competitors. BTG will now use its US sales force, which in recent years has been expanded in order to boost sales of varicose veins treatment Varithena. Analysts are yet to update forecasts, but think that medium-term Ekos sales could come in a long way ahead of expectations.
